Core Viewpoint - Allergy Therapeutics PLC is positioned well in the allergy immunotherapy market, demonstrating stable revenue and a strong market position despite shifts in product registration in Germany [3][5]. Financial Performance - The company reported an earnings per share (EPS) of -$0.007, which matched the estimated EPS [1][5]. - Revenue for the year ending June 2025 was reported at £55 million, stable compared to the previous year, with a 2% increase when adjusted for constant exchange rates [2]. Market Dynamics - There has been a rapid shift in Germany from non-registered to fully registered allergy immunotherapy products, altering the company's product mix more swiftly than anticipated [3]. - Demand for Allergy Therapeutics' registered treatments remains strong, indicating a solid market position [3][5]. Financial Position - The company has significantly strengthened its balance sheet by repaying a £55 million shareholder loan facility and securing a new £50 million uncommitted loan facility [4][5]. - This financial flexibility is crucial as the company prepares for a key decision in 2026 [4].

ALK (ALKB:DC / OMX: ALK B) today announced that Health Canada has approved ALK’s regulatory filing for ITULATEK® (tree pollen sublingual allergy immunotherapy tablet) for treatment of children and adolescents aged five to 17. Accordingly, the tree pollen tablet is now indicated for treatment of moderate to severe seasonal allergic rhinitis, with or without conjunctivitis, induced by pollen from birch, alder, hazel, and/or oak, in children, adolescents, and adults five to 65 years of age in Canada. Outside ...